← Leaderboards
Maneesh Jain
University Of Nebraska Medical Center
$6,905,007
Attributed
$13,712,383
Total exposure
11
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,712,383 · 11
By mechanism
R01$6,240,933 · 3
U01$2,652,788 · 1
R44$2,164,803 · 2
P01$1,252,951 · 1
P20$673,303 · 1
R21$354,105 · 1
Top collaborators
- Surinder Kumar Batra10 shared
- Balaji Narasimhan5 shared
- Aliasger K Salem5 shared
- Ravi Salgia5 shared
- Wade M Junker3 shared
- Aaron R Sasson3 shared
- Jered C Garrison2 shared
- Joshua James Souchek2 shared
Most similar at University Of Nebraska Medical Center
Same institution · by research overlap
- Michael A Hollingsworth$34,707,253
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant Neoplasm Of PancreasMalignant NeoplasmsBaseOverexpressionMouse ModelPancreatic NeoplasmPancreasTreatment EfficacyCancer CellPharmaceutical PreparationsIn VivoDiagnosisMucinsNeoplastic CellCellsCancer TherapyTumor AntigensDesignEvaluationClinical TrialsTargeted TreatmentAntibodiesOutcome Forecast
Grant awards (34)
Lysosome Trapped FAP-Targeted Theranostics for Pancreatic Cancer$626,716
R01 · FY2025 · CA
Lysosome Trapped FAP-Targeted Theranostics for Pancreatic Cancer$621,119
R01 · FY2024 · CA
Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer$573,438
R01 · FY2024 · CA · contact PI
Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer$535,359
R01 · FY2023 · CA · contact PI
Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer$535,359
R01 · FY2022 · CA · contact PI
Core 2: Animal Model and Experimental Therapeutics Core [AMETC]$248,086
P01 · FY2022 · CA · contact PI
Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer$567,785
R01 · FY2021 · CA · contact PI
Nanovaccine platforms to combat pancreatic cancer$507,337
U01 · FY2021 · CA
Core 2: Animal Model and Experimental Therapeutics Core [AMETC]$253,150
P01 · FY2021 · CA · contact PI
Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer$614,511
R01 · FY2020 · CA · contact PI
Nanovaccine platforms to combat pancreatic cancer$506,063
U01 · FY2020 · CA
Core 2: Animal Model and Experimental Therapeutics Core [AMETC]$253,150
P01 · FY2020 · CA · contact PI
MUC4/16 assay for the early diagnosis and management of benign and malignant pancreatic diseases$657,713
R44 · FY2019 · DK
Seromic Mucin Signature for the Early Diagnosis of Pancreatic Cancer$650,357
R44 · FY2019 · CA
Nanovaccine platforms to combat pancreatic cancer$529,150
U01 · FY2019 · CA
Targeted Radiation Therapy for Pancreatic Cancer$422,866
R01 · FY2019 · CA
Core 2: Animal Model and Experimental Therapeutics Core [AMETC]$245,554
P01 · FY2019 · CA · contact PI
Combinatorial Biomarkers for Malignant Polyps and Colon Cancer Detection$225,000
R43 · FY2019 · CA
MUC4/16 assay for the early diagnosis and management of benign and malignant pancreatic diseases$657,713
R44 · FY2018 · DK
Nanovaccine platforms to combat pancreatic cancer$543,977
U01 · FY2018 · CA
Targeted Radiation Therapy for Pancreatic Cancer$435,945
R01 · FY2018 · CA
Core 2: Animal Model and Experimental Therapeutics Core [AMETC]$253,011
P01 · FY2018 · CA · contact PI
Nanovaccine platforms to combat pancreatic cancer$566,261
U01 · FY2017 · CA
Targeted Radiation Therapy for Pancreatic Cancer$435,945
R01 · FY2017 · CA
MUC4/16 assay for the early diagnosis and management of benign and malignant pancreatic diseases$199,020
R44 · FY2017 · DK
Targeted Radiation Therapy for Pancreatic Cancer$435,945
R01 · FY2016 · CA
Targeted Radiation Therapy for Pancreatic Cancer$435,945
R01 · FY2015 · CA
Project 8 - MUC4 Nanovaccine for Pancreatic Cancer$224,600
P20 · FY2015 · GM · contact PI
Project 8 - MUC4 Nanovaccine for Pancreatic Cancer$224,993
P20 · FY2014 · GM · contact PI
Project 8 - MUC4 Nanovaccine for Pancreatic Cancer$223,710
P20 · FY2013 · GM · contact PI
Novel Combination Therapy Against Pancreatic Cancer$193,202
R21 · FY2012 · CA · contact PI
Novel Combination Therapy Against Pancreatic Cancer$160,903
R21 · FY2011 · CA · contact PI
EGFRvIII in Pancreatic Cancer$74,250
R03 · FY2010 · CA · contact PI
EGFRvIII in Pancreatic Cancer$74,250
R03 · FY2009 · CA · contact PI